4[1]Ross R. Atherosclerosis-An inflammatory disease. N Eng J Med, 1999, 340 (2): 115-126
5[2]Laman JD, De Smet BJ, Schoneveld A, Van Meurs M. CD40-CD40L interactions in atherosclerosis. Immunol Today, 1997, 18 (6): 272-277
6[3]Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implication for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA, 1997, 94 (5): 1 931-936
7[4]Rosenson RS,Tangney CC. Antiatherothrombotic properties of statins: implication for cardiovascular event reduction. JAMA, 1998, 279 (20): 1 643-650
8[5]Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet, 1996, 348 (9034): 1 079-082
9[6]Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatheosclerotic activties independent of plasma cholesterol lowering. Arteroscler Thromb Vasc Biol, 2001, 21 (1): 115-121
10[7]LutgensE, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA, 2000, 97 (13): 7 464-469
